Europe Meningococcal Vaccines Market Size & Outlook
Global Market
Related Markets
Europe meningococcal vaccines market highlights
- The Europe meningococcal vaccines market generated a revenue of USD 1,065.2 million in 2025.
- The market is expected to grow at a CAGR of 5.1% from 2026 to 2033.
- In terms of segment, menveo was the largest revenue generating brand in 2025.
- Nimenrix is the most lucrative brand segment registering the fastest growth during the forecast period.
- Country-wise, Sweden is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 1,065.2 million |
| Market revenue in 2033 | USD 1,626.5 million |
| Growth rate | 5.1% (CAGR from 2026 to 2033) |
| Largest segment | Menveo |
| Fastest growing segment | Nimenrix |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Menactra, Menveo, Nimenrix, Trumenba, Bexsero |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.3% of the global meningococcal vaccines market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,007.4 million by 2033.
The presence of sophisticated technology, well-established research infrastructure, and strong market players in Europe regions is responsible for market growth. Moreover, rising awareness about meningococcal vaccine coupled with increasing prevalence of this disease is expected to boost market growth.
Approval of new vaccines that are affordable and have similar immune response & reduced schedule is expected to propel market growth. For instance, in November 2020, the European Commission approved Men Quadfi for individual aged 12 months and above against serogroups A, C, W, & Y.
Moreover, in June 2018, GlaxoSmithKline plc received approval from European Commission for Bexsero. Thus, increasing approval of novel products in the region is expected to drive market growth over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | www.seruminstitute.com/ |
| Walvax Biotechnology | View profile | 11-50 | Kunming, Yunnan, China, Asia | www.walvax.com |
Europe Meningococcal Vaccines Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Meningococcal Vaccines Market Outlook will help companies and investors design strategic landscapes.
Menveo was the largest segment with a revenue share of 32.14% in 2025.
Horizon Databook has segmented the Europe meningococcal vaccines market based on menactra, menveo, nimenrix, trumenba, bexsero covering the revenue growth of each sub-segment from 2021 to 2033.
The presence of sophisticated technology, well-established research infrastructure, and strong market players in Europe regions is responsible for market growth. Moreover, rising awareness about meningococcal vaccine coupled with increasing prevalence of this disease is expected to boost market growth.
Approval of new vaccines that are affordable and have similar immune response & reduced schedule is expected to propel market growth. For instance, in November 2020, the European Commission approved Men Quadfi for individual aged 12 months and above against serogroups A, C, W, & Y.
Moreover, in June 2018, GlaxoSmithKline plc received approval from European Commission for Bexsero. Thus, increasing approval of novel products in the region is expected to drive market growth over the forecast period.
- Europe Meningococcal Vaccines Market Brand Outlook (Revenue, USD Million , 2021-2033)
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
- Europe Meningococcal Vaccines Market Serotype Outlook (Revenue, USD Million , 2021-2033)
- A
- B
- C
- W-135
- Y
- Europe Meningococcal Vaccines Market Age Group Outlook (Revenue, USD Million , 2021-2033)
- Infants (0 to 2 years)
- Children and Adults (2 years and above)
- Europe Meningococcal Vaccines Market Sales Channel Outlook (Revenue, USD Million , 2021-2033)
- Private
- Public
- Europe Meningococcal Vaccines Market Type Outlook (Revenue, USD Million , 2021-2033)
- Bivalent
- Quadrivalent
- Others
Reasons to subscribe to Meningococcal Vaccines Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Meningococcal Vaccines Market Outlook databook
- Our clientele includes a mix of Meningococcal Vaccines Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Meningococcal Vaccines Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Meningococcal Vaccines Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Meningococcal Vaccines Market, 2021-2033 (US$M)
Europe Brand - Meningococcal Vaccines Market Statistics, 2025 - 2033 (US$M)
